The valuation assigned is $3.26 on an undiluted basis and $2.13 on a fully diluted basis. They have Melanoma & CCRCC program assumptions which are incorrect. I feel like I spent time 10 mins reading this report which I will not get back.
Dr.T - is it the 100% success potential that MST has assigned to RC220 that prompted you to send a newsletter? Apart from that, it reads like a nice fiction.
The valuation assigned is $3.26 on an undiluted basis and $2.13...
-
- There are more pages in this discussion • 108 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.50 |
Change
0.040(2.74%) |
Mkt cap ! $255.5M | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.52 | $1.49 | $55.22K | 36.85K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2057 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.50 | 1217 | 3 |
View Market Depth
| Last trade - 11.47am 21/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |